Pfizer (PFE -5.12%) received great news last Thursday that an advisory committee to the U.S. Food and Drug Administration (FDA) overwhelmingly recommended Emergency Use Authorization (EUA) for its COVID-19 vaccine. That news was followed by the FDA granting EUA to Pfizer's vaccine over the weekend. But Pfizer's shares slipped on both Friday and Monday after these positive developments. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss why Pfizer stock didn't jump following the good news.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Corrine Cardina: Keith, what have you noticed about the market's reaction so far. I was a little bit surprised to see Pfizer stock just down a hair this morning. Do you think maybe the market had just bid it up so far in anticipation? Now we're just seeing the catalyst in the rearview mirror, what's going on?
Keith Speights: Well, Corinne, there's an old saying among investors: "Buy the rumor. Sell the news." I think we're probably seeing a little bit of that today.
Like I said, everyone has expected this to come about. Everyone expected the Advisory Committee to recommend approval or recommend authorization, rather, for Pfizer's vaccine. Because those expectations were already in investors' minds, I think once the news arrived, it was like, "Okay, now what?"
I think that's where we are. We're in the "OK, now what" stage. What's next? I think that's why you also saw Moderna stock rise a little this morning because now investors are looking for what's next with Moderna. The advisory committee meets to review their vaccine next week. We always talk about the stock market being forward-looking. I think that's exactly what we're seeing with the movement of some of these stocks this morning.